RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SAR440340/REGN3500/ITEPEKIMAB (ANTI- IL-33 MAB) IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- 27472 Schoenherr, Ste 100. Warren, MI. 48088-6854.
- (586) 751-8844